- American City Business Journals•last month
Shares of Duke University spinout Aerie Pharmaceuticals (AERI) have been trending upward for the past month, this week notwithstanding, and the the drug developer announced favorable news Thursday morning that shows it is on track with a late-stage trial. Finding the right patients who are both willing and meet the proper profile for a clinical trial can be difficult, and reaching the enrollment milestone keeps Aerie on schedule for an interim trial readout in the fourth quarter. Aerie is developing an eye drop named Rhopressa as a treatment for glaucoma and announced that it has enrolled 700 patients in a Phase 3 clinical trial in which it is testing Rhopressa against the existing treatment timolol.
- Benzinga•last month
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) disclosed the completion of patient enrollment in Rocket 4, its final stage clinical study for RhopressaTM (netarsudil ophthalmic solution) 0.02% intended to ...
Aerie Pharmaceuticals, Inc.NasdaqGM
After hours: 17.290.00 (0.00%) as of 4:31 PM EDT
|Bid||14.11 x 300|
|Ask||20.00 x 100|
|52wk Range||10.82 - 33.25|
|Day's Range||17.27 - 18.34|
|Avg Vol (3m)||351,914|
As of 4:00 PM EDT. Market closed.